Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide 2.4 mg) is designed to reduce appetite, but many people still experience hunger at some point during treatment — especially in the early weeks or after a dose increase. That is entirely normal. Semaglutide works by activating GLP-1 receptors that signal fullness to the brain and slow gastric emptying, but hunger is complex, and the medicine does not switch it off completely for everyone. These are prescription-only medicines that require clinical assessment before starting; how hunger responds to treatment varies from person to person and is one of the things a prescriber watches across your care.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen of Wegovy delivers 0.25 mg weekly. It exists to let your body adjust to the medicine, not to produce noticeable appetite changes. Most people feel little difference at this stage, and some find hunger actually fluctuates more than usual as the gut adapts. That is not a sign the medicine is wrong for you.
Semaglutide takes roughly four to five weeks at any given dose level to reach a stable concentration in the blood. So even once you move to 0.5 mg, then 1.0 mg, the full effect of each step builds over the following month. Expecting dramatic hunger suppression from week one sets an unfair benchmark. The full Wegovy overview explains the titration pathway in more detail.
What helps most in this phase is routine: eating at regular intervals, keeping meals protein-rich to extend natural fullness, and drinking water before each meal. The medicine is doing groundwork you cannot yet feel.
By the time most people reach the 1.7 mg or 2.4 mg dose, appetite suppression tends to be more consistent. Meals feel satisfying with smaller portions. The urge to snack between meals often reduces noticeably. Many people describe forgetting to eat, which is quite different from white-knuckling through hunger.
That said, hunger does not vanish entirely. Physical hunger (the kind produced by an empty stomach and falling blood sugar) may still appear, especially if a meal is delayed. What semaglutide reliably reduces is the intensity of that signal and the speed at which it escalates to urgent. The research underpinning Wegovy's licence, including the STEP 1 trial published in the New England Journal of Medicine, showed meaningful average weight loss over 68 weeks, but participants still ate; appetite was modulated, not eliminated.
Head hunger is a separate challenge. Wegovy has less influence over emotional eating, habit-driven snacking, or eating out of boredom. Identifying which type of hunger you are experiencing (physical versus psychological) helps you respond to it more usefully during this phase.
A noticeable return of hunger, particularly in the days before your next weekly injection, is one of the more common questions our prescribers hear. It can indicate that your current dose is the right one to review upward, or it can simply reflect that your body has adjusted to the medicine's effect at this level. Neither conclusion should be drawn without clinical input.
It is worth reading about why Wegovy can sometimes make hunger feel worse before assuming the medicine is not working. There are also patterns worth knowing about specific hunger pains on Wegovy that point to gastrointestinal side effects rather than true appetite return.
If hunger has returned alongside a plateau on the scales, the two are often connected. Detailed guidance on stalling on Wegovy covers what the evidence says about that combination. The NHS's guidance on semaglutide is a useful reference for what to report to your prescriber and when.
Never adjust your injection timing or dose yourself. If hunger feels unmanageable, raise it with your prescriber at the next review, or sooner through aftercare, which at nume is available seven days a week.
Wegovy reduces hunger as a means to an end) sustainable weight loss alongside a reduced-calorie diet and increased activity. The STEP 1 trial reported an average body-weight reduction of around 15% over 68 weeks; that result was achieved with meaningful, ongoing effort from participants, not passive appetite suppression alone. Hunger management is part of the work, not a problem the medicine solves on your behalf.
Understanding how semaglutide interacts with hunger signals more broadly can help frame what you are experiencing as treatment progresses. And if you are reaching a point where the medicine seems to have stopped helping altogether, there is useful context on what to do when Wegovy stops working.
If you have not yet started treatment and want to understand whether Wegovy is clinically suitable for you, the cost context is worth understanding too, our guide to Wegovy pricing in the UK explains what a legitimate private prescription includes. When you are ready, you can check your eligibility with our prescribers, who review every consultation personally, the same day it arrives.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.